NASDAQ:IOVA 3 November 2025 - 23 December 2025

Iovance Biotherapeutics shares jumped 12.1% to close at $2.78 on Dec. 22, with pre-market trading near $2.80. Short interest stands at 33.4% of the float, or about 118.94 million shares, according to MarketBeat. Barclays raised its price target to $10 and kept an Overweight rating. Iovance also announced inducement stock options for four new employees at a $2.46 exercise price.

Iovance Biotherapeutics shares surged 12% to close at $2.52 on Dec. 17, trading over 23 million shares after Barclays raised its price target to $10. The stock remains down 65% over the past year, with a 52-week range of $1.64 to $8.15. Analyst consensus stands at “Hold,” with an average 12-month target of $11.10.

Iovance shares traded near $2.00 on Nov. 3, 2025, with a market cap around $700 million after plunging 70% year-to-date. The company’s Amtagvi, the first FDA-approved TIL therapy for advanced melanoma, also secured Health Canada approval. Interim Phase 2 data showed a 25.6% response rate for lifileucel in advanced NSCLC. Iovance will hold its Q3 earnings call on Nov. 6.